Adalimumab (HUMIRA): a review.

Article Details

Citation
Copy to clipboard

Scheinfeld N

Adalimumab (HUMIRA): a review.

J Drugs Dermatol. 2003 Aug;2(4):375-7.

PubMed ID
12884458 [ View in PubMed
]
Abstract

Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.

DrugBank Data that Cites this Article

Drugs